MOTS-c vs SS-31
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Mitochondrial ORF of the 12S rRNA type-c
MOTS-c is a 16-amino-acid peptide your own mitochondria make, encoded inside the 12S rRNA region of mitochondrial DNA and discovered in 2015. It is studied as a metabolic regulator and a so-called exercise mimetic, because its levels rise when you work out and it improves insulin sensitivity in animals. The catch: the impressive results are almost entirely in mice, with no completed published human efficacy trials.
Also: Elamipretide, Bendavia
SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2), known generically as elamipretide and sold as FORZINITY, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. It works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more ATP with less oxidative damage. This is the rare research peptide with a real regulatory finish line: the FDA granted it accelerated approval in September 2025 for Barth syndrome, though it has failed several other major trials.
Key Comparison Insights
- SS-31 is FDA approved, while MOTS-c remains in research stages.
- MOTS-c is categorized as Hormonal, while SS-31 is Anti-Aging.
- SS-31 has stronger research evidence (FDA Approved) compared to MOTS-c (Animal Studies).
Detailed Comparison
| Attribute | MOTS-c | SS-31 |
|---|---|---|
| Category | Hormonal | Anti-Aging |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | MOTS-c works largely through the AMPK pathway, the cell's main energy and fuel-gauge system. The proposed route is that MOTS-c interferes with the folate-AICAR-one-carbon metabolism cycle, which raises AICAR and activates AMPK in skeletal muscle, liver, and fat. Once AMPK is switched on, cells burn more fatty acids, take up more glucose, and ramp up mitochondrial biogenesis. MOTS-c can also move into the cell nucleus under metabolic stress and influence stress-response genes, which is unusual for a mitochondrial peptide and is part of why it is framed as a stress-adaptive signal. Treat the exact pathway details as a working model rather than settled fact, since much of it is still being mapped. | SS-31 is a cell-permeable, mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and binds tightly to cardiolipin. Cardiolipin is essential for keeping the membrane's folded cristae structure intact and for organizing the proteins of the electron transport chain that generate ATP. By stabilizing cardiolipin, SS-31 helps preserve cristae shape, reduces the electron leakage that produces reactive oxygen species, and supports more efficient ATP production. Studies also suggest it modulates the membrane's surface electrostatics and can limit opening of the mitochondrial permeability transition pore, a trigger for cell death, though the full mechanistic picture is still being worked out. |
| Common Dosing | 5-10 mg weekly 1-3x weekly | 40 mg subcutaneous daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection or IV infusion |
| Typical Duration | Variable by protocol | Variable by condition |
| Best Time to Take | Morning or pre-workout | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | In mice, MOTS-c is genuinely impressive: it improves insulin sensitivity, protects against diet-induced obesity, and older animals given MOTS-c run longer on a treadmill, which is where the exercise-mimetic label comes from. The human story is much thinner. The strongest human finding is observational: exercise raises MOTS-c, with reports of roughly a 12-fold jump in skeletal muscle and about a 1.6-fold rise in circulation after exercise, suggesting it may be one natural messenger behind some exercise benefits. But that is correlation, not proof that injecting MOTS-c reproduces those benefits. As of 2026 there are no completed, published randomized human trials showing that supplemental MOTS-c causes weight loss, better metabolic health, or longer life in people. It is also a known anti-doping target, which tells you it is treated as experimental and performance-relevant, not as an established therapy. | Unlike most peptides in this space, SS-31 has been through extensive human trials, with a mixed but consequential record. In TAZPOWER, a randomized placebo-controlled crossover study in Barth syndrome, elamipretide improved skeletal muscle strength and cardiac stroke volume, and the long open-label extension showed sustained benefit, which ultimately supported FDA accelerated approval in September 2025 as the first treatment for that ultra-rare disease. It has also failed prominently: the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy missed its primary endpoints on the six-minute walk test, the ReCLAIM trial in dry age-related macular degeneration did not hit its primary endpoints, and a heart-failure trial (PROGRESS-HF) also missed its primary endpoint. Across these studies the drug was generally well tolerated, with mostly mild effects such as injection-site reactions, headache and nausea. The accurate summary is that SS-31 is a validated mitochondrial-targeting peptide with one approved indication and a string of negative trials elsewhere, so its benefit appears to depend heavily on the specific disease. |
Frequently Asked Questions: MOTS-c vs SS-31
What is the difference between MOTS-c and SS-31?
MOTS-c is a hormonal peptide that mots-c is a 16-amino-acid peptide your own mitochondria make, encoded inside the 12s rrna region of mitochondrial dna and discovered in 2015. it is studied as a metabolic regulator and a so-called exercise mimetic, because its levels rise when you work out and it improves insulin sensitivity in animals. the catch: the impressive results are almost entirely in mice, with no completed published human efficacy trials. SS-31 is a anti-aging peptide that ss-31 (sequence d-arg-dmt-lys-phe-nh2), known generically as elamipretide and sold as forzinity, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. it works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more atp with less oxidative damage. this is the rare research peptide with a real regulatory finish line: the fda granted it accelerated approval in september 2025 for barth syndrome, though it has failed several other major trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, MOTS-c or SS-31?
Neither is universally "better" - the choice depends on your specific goals. MOTS-c is typically used for hormonal purposes, while SS-31 is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can MOTS-c and SS-31 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using MOTS-c and SS-31 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.